先进疗法推动监管边界的发展：新型治疗方法需要更多的监管灵活性和透明度。
Advanced therapies push regulatory boundaries: Novel therapeutic approaches require more regulatory flexibility and transparency.
机构信息
London, UK.
出版信息
EMBO Rep. 2017 Dec;18(12):2101-2104. doi: 10.15252/embr.201745345. Epub 2017 Nov 9.
Abstract
Novel therapies, such as gene or cell therapy, don not require radical changes of the regulatory framework for medicinal products. Yet, both new and old developments cannot be easily accommodated by existing regulations.[Image: see text]
摘要
新型疗法，如基因或细胞疗法，并不需要对药物监管框架进行重大改变。然而，新的和旧的发展都不能轻易被现有法规所容纳。[图片：见正文]
相似文献
1
Advanced therapies push regulatory boundaries: Novel therapeutic approaches require more regulatory flexibility and transparency.先进疗法推动监管边界的发展：新型治疗方法需要更多的监管灵活性和透明度。
EMBO Rep. 2017 Dec;18(12):2101-2104. doi: 10.15252/embr.201745345. Epub 2017 Nov 9.
2
The evolution of nonclinical regulatory science: advanced therapy medicinal products as a paradigm.非临床监管科学的演变：以高级治疗药品为例
Mol Ther. 2013 Sep;21(9):1644-8. doi: 10.1038/mt.2013.175.
3
Clinical success of complex biological therapies: be careful what you wish for..复杂生物疗法的临床成功：愿望需谨慎。
Mol Ther. 2010 Oct;18(10):1737-8. doi: 10.1038/mt.2010.204.
4
Innovation and competition in advanced therapy medicinal products.先进治疗药物的创新与竞争。
EMBO Mol Med. 2019 Mar;11(3). doi: 10.15252/emmm.201809992.
5
ESGCT 2017 in Berlin: Clear Steps Forward.2017年于柏林举行的欧洲骨与软组织肿瘤学会会议：明确的前进步伐。
Mol Ther. 2017 Dec 6;25(12):2599. doi: 10.1016/j.ymthe.2017.11.003. Epub 2017 Nov 28.
6
Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.比较欧盟和美国批准先进疗法的监管途径。
Cytotherapy. 2021 Mar;23(3):261-274. doi: 10.1016/j.jcyt.2020.11.008. Epub 2021 Jan 19.
7
Regulatory watch: European regulatory experience with advanced therapy medicinal products.监管观察：欧洲在先进治疗药品方面的监管经验
Nat Rev Drug Discov. 2019 Jan;18(1):8-9. doi: 10.1038/nrd.2018.200. Epub 2018 Nov 30.
8
Biological therapies for inherited diseases: social and bioethical considerations. Hemophilia as an example.遗传性疾病的生物疗法：社会与生物伦理考量。以血友病为例。
Expert Opin Biol Ther. 2015 May;15(5):713-22. doi: 10.1517/14712598.2015.1029451. Epub 2015 Mar 31.
9
Advanced Therapy Products in Brazil: Regulatory Aspects.巴西的先进治疗产品：监管方面。
Adv Exp Med Biol. 2023;1430:117-133. doi: 10.1007/978-3-031-34567-8_7.
10
Global Regulatory Differences for Gene- and Cell-Based Therapies: Consequences and Implications for Patient Access and Therapeutic Innovation.基于基因和细胞疗法的全球监管差异：对患者获得治疗和治疗创新的影响及后果
Clin Pharmacol Ther. 2018 Jan;103(1):120-127. doi: 10.1002/cpt.894. Epub 2017 Nov 6.
本文引用的文献
1
Phage therapy: awakening a sleeping giant.噬菌体疗法：唤醒沉睡的巨人。
Emerg Top Life Sci. 2017 Apr 21;1(1):93-103. doi: 10.1042/ETLS20170002.
2
The Current Use of Stem Cells in Bladder Tissue Regeneration and Bioengineering.干细胞在膀胱组织再生与生物工程中的当前应用
Biomedicines. 2017 Jan 6;5(1):4. doi: 10.3390/biomedicines5010004.
3
Safety of Cultivated Limbal Epithelial Stem Cell Transplantation for Human Corneal Regeneration.用于人类角膜再生的培养角膜缘上皮干细胞移植的安全性
Stem Cells Int. 2017;2017:6978253. doi: 10.1155/2017/6978253. Epub 2017 Mar 30.
4
Compassionate use of experimental therapies: who should decide?实验性疗法的同情使用：应由谁来决定？
EMBO Mol Med. 2015 Oct;7(10):1248-50. doi: 10.15252/emmm.201505262.
5
Stem cells: taking a stand against pseudoscience.干细胞：坚决抵制伪科学。
Nature. 2014 Jun 19;510(7505):333-5. doi: 10.1038/510333a.
6
Recombinant viral vaccines for cancer.用于癌症的重组病毒疫苗。
Trends Mol Med. 2012 Sep;18(9):564-74. doi: 10.1016/j.molmed.2012.07.007. Epub 2012 Aug 21.
Zotero 插件